Novel quinolinone-phosphonic acid AMPA antagonists devoid of nephrotoxicity

Farmaco

Volumn 57, Issue 10, 2002, Pages 787-802

  Cordi, Alex A ^a   Desos, Patrice ^a   Ruano, Elisabeth ^a   Al Badri, Hashim ^b,f   Fugier, Claude ^c   Chapman, Astrid G ^d   Meldrum, Brian S ^d   Thomas, Jean Yves ^e   Roger, Anita ^e   Lestage, Pierre ^e  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b IRCOF   (France)

^c ORIL   (France)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^f 6 Bd du Maréchal Juin   (France)

Author keywords

2 (1H) Oxoquinoline; AMPA antagonist; Anticonvulsant; Nephrotoxicity; Phosphonic acid

Indexed keywords

6 (AMINOSULFONYL) 7 CHLORO 2 OXO 1,2 DIHYDROQUINOLIN 3 YLPHOSPHONIC ACID; 6 [(2 ACETYLHYDRAZINO)SULFONYL] 7 CHLORO 2 OXO 1,2 DIHYDROQUINOLIN 3 YLPHOSPHONIC ACID; 6 [(BENZOYLAMINO)SULFONYL] 7 CHLORO 2 OXO 1,2 DIHYDROQUINOLIN 3 YLPHOSPHONIC ACID; 6,7 DICHLORO 2(1H) OXOQUINOLONE 3 PHOSPHONIC ACID; 7 CHLORO 6 [(HYDROXYAMINO)SULFONYL] 2 OXO 1,2 DIHYDROQUINOLIN 3 YLPHOSPHONIC ACID; AMPA RECEPTOR ANTAGONIST; CHLORINE; DIETHYL 6 [(BENZYLOXY)AMINO]SULFONYL 7 CHLORO 2 OXO 1,2 DIHYDROQUINOLIN 3 YLPHOSPHONIC ACID; PROBENECID; QUINOLINOL DERIVATIVE; S 17625; UNCLASSIFIED DRUG; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTICONVULSIVE AGENT; PHOSPHONIC ACID DERIVATIVE; QUINOLONE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IN VIVO STUDY; KIDNEY FUNCTION; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OOCYTE; PROTECTION; RAT; STROKE; STRUCTURE ACTIVITY RELATION; XENOPUS; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DBA MOUSE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FISCHER 344 RAT; IC 50; KIDNEY; METABOLISM; SEIZURE;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INHIBITORY CONCENTRATION 50; KIDNEY; MICE; MICE, INBRED DBA; OOCYTES; PHOSPHONIC ACIDS; QUINOLONES; RATS; RATS, INBRED F344; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; XENOPUS;

EID: 0037167777     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(02)01281-8     Document Type: Article

References (40)

1. Krogsgaard-Larsen P. Amino acid receptors. Hansh C. Comprehensive Medicinal Chemistry. III:1990;521-537 Pergamon Press, Oxford.
2. Hollmann M., O'Shea-Greenfield A., Rogers S.W., Heineniann S. Cloning by functional expression of a member of the glutamate receptor family. Nature. 342:1989;643-648.
3. Moriyoshi K., Masu M., Ishii T., Shigemoto R., Mizuno N., Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 354:1991;31-37.
4. Conn P.J., Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. Sci. 37:1997;205-237.
5. Croucher M.J., Collins J.F., Meldrum B.S. Anticonvulsant action of excitatory amino acid antagonists. Science. 216:1982;899-901.
6. Troupin A.S., Mendius J.R., Cheng F., Risinger M.W. MK-801. Meldrum B.S., Porter R.J. Current Problems in Epilepsy 4: New Anticonvulsant Drugs. 1986;191-201 John Libbey, London.
7. Herrling P.L. Competitive NMDA antagonists: results from animal models and first results in humans. J. Neurochem. 61:(Suppl.):1993;S283C.
8. Clark W.M., Coull B.M. Randomized trial of CGS 19755, a glutamate antagonist, in acute ischemic stoke treatment. Neurology. 44:(Suppl. 2):1994;A270.
9. Sheardown M.J., Suzdak P.D., Nordholm L. AMPA but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h. Eur. J. Pharmacol. 236:1993;347.
10. Gill R. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc. Brain Metabol. Rev. 6:1994;225-256.
11. Chimirri A., Gotto R., Zappalà M. AMPA receptors antagonists. Exp. Opin. Ther. Patents. 9:1999;557-570.
12. Auberson Y. Competitive AMPA antagonism: a novel mechanism for antiepileptic drugs? Drugs Future. 26:2001;463-471.
13. Sheardown M.S., Nielsen E.O., Hansen A.J., Jacobsen P., Honoré T. 2,3-Dihydro-6-nitro-7-sulfanioyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
14. S. Sakamoto, J. Omori, M. Shimizu-Sasamata, M. Okada, S. Kawasaki, S. Yatsugi, K. Hidaka, K. Togami, S. Tada, S. Usuda, K. Murase, Imidazolylquinoxaline-2,3-diones: novel and potent antagonists of α-amino-3-hydroxy-5-niethylisoxazole-4-propionate (AMPA) excitatory amino acid receptor. XIIth International Symposium on Medicinal Chemistry, Basel, 1992, P-022A.
15. Ohmori J., Sakamoto S., Kubota H., Shimizu-Sasamata M., Okada M., Kawasaki S., Hidaka K., Togami K., Furuya T., Murase K. 6-(1H-Imidazoli-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 37:1994;467-475.
16. Desos P., Lepagnol J.M., Morain P., Lestage P., Cordi A.A. Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-quinolone-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. J. Med. Chem. 39:1996;197-206.
17. Cordi A.A., Desos P., Randle J.C.R., Lepagnol J. Structure-activity relationships in a series of 3-sulfonylamino-2-(1H)-quinolones as new AMPA/kainate and glycine antagonists. Bioorg. Med. Chem. 3:1995;129-141.
18. Lepagnol J.M., Roger A.M., Cordi A.A., Lestage P.J. Post-ischemic treatment with S 17625-2, a new AMPA receptor antagonist, protects the rat brain after permanent focal ischemia. J. Cereb. Blood Flow Metab. 15:(Suppl. 1):1995;S373.
19. Morain P. S 17625, a selective and competitive non-NMDA antagonist: cerebral anti-ischemic effects in rodents. Br. J. Pharmacol. 114:(Suppl.):1995;Abst 330P.
20. Lepagnol J., Roger A., Rivet J.-M., Lestage P. Delayed intravenous treatment with S 17625-2 a competitive AMPA receptor antagonist, reduces infarction after permanent focal ischemia in rats. Soc. Neurosci. Abst. 21:1995;Abst. 145.2.
21. Moller J.V., Sheikh M.I. Renal organic anion transport system: pharmacological, physiological and biochemical aspects. Pharmacol. Rev. 34:1983;315-358.
22. Fowler L.M., Foster J.R., Lock E.A. Effect of ascorbic acid, acivicin and probenecid on the nephrotoxicity of 4-aminophenol in the Fisher 344 rat. Arch. Toxicol. 67:1993;613-621.
23. Fowler L.M., Foster J.R., Lock E.A. Nephrotoxicity of 4-amino-3-S-gluthathionylphenol and its modulation by metabolism or transport inhibitors. Arch. Toxicol. 68:1994;15-23.
24. Trumper L., Monasterolo L.A., Ellas M.M. Probenecid protects against in vivo acetaminophen-induced nephrotoxicity in male Wistar rats. J. Pharmacol. Exp. Ther. 284:1998;606-610.
25. Stewart Goodwin C., Raftery E.B., Goldberg A.D., Skeggs H., Till A.E., Martin C.M. Effects of rate of infusion and probenecid on serum levels, renal excretion and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. Antimicrob. Agents Chemother. 6:1974;338-346.
26. Aherne G., Piall E., Marks V., Mould W., White W.F. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br. Med. J. 1:1978;1097-1099.
27. Zamboni W.C., Houghton P.J., Johnson R.K., Hulstein J.L., Crom W.R., Cheshire P.J., Hanna S.K., Richmond L.B., Luo X., Stewart C.F. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J. Pharmacol. Exp. Ther. 284:1998;89-94.
28. C.F. Bigge, G. Johnson, C.P. Taylor, D.F. Welty, Pharmaceutical Preparation Containing an Uricosuric and an Excitatory Amino Acid Antagonist. W09304688.
29. Taylor C.P., Vartanian M.G. Probenecid pretreatment enhances anticonvulsant action of NBQX in mice. Eur. J. Pharmacol. 213:1992;151-153.
30. Carretero J.C., Garcia-Ruano J.L., Vicioso M. A practical route to C-8 substituted fluoroquinolones. Tetrahedron. 48:1992;7373-7382.
31. Ramadas K., Srinivasan N. Iron-ammonium chloride - a convenient and inexpensive reductant. Synth. Commun. 22:1992;3189-3195.
32. Saari W.S., Schwering J.E. A convenient synthesis of nitro-substituted 1,2-benzisothiazol-3(2H)-one 1,1-dioxides (nitrosaccharins). J. Heterocyclic Chem. 23:1986;1253-1255.
33. Darses S., Jeffery T., Genet J.-P., Brayer J.-L., Demoute J.-P. Cross-coupling of arenediazonium tetrafluoroborates with arylboronic acids catalysed by palladium. Tetrahedron Lett. 37:1996;3857-3860.
34. Sengupta S., Bhattacharyya S. Palladium-catalyzed cross-coupling of arenediazonium salts with arylboronic acids. J. Org. Chem. 62:1997;3405-3406.
35. Y. Takano, 6-Arylquinoline Carboxylate Derivatives and their Addition Salts and their Preparation Method. JP 2000 169450.
36. Verdoorn T.A., Dingledine R. Excitatory amino acid receptors expressed in Xenopus oocytes: agonist pharmacology. Mol. Pharmacol. 34:1988;298-307.
37. Wallace R.A., Jared D.W., Dumont J.N., Sega M.W. Protein incorporation by isolated amphibian oocytes III. Optimum incubation conditions. J. Exp. Zool. 184:1973;321-334.
38. Collins A.J., Horlington M. A sequential screening test based on the running component of audiogenic seizures in mice, including reference compounds PD50 values. Br. J. Pharmacol. 37:1969;140-150.
39. Loscher W., Meldrum B.S. Evaluation of anticonvulsant drugs in genetic animal models of epilepsy. Fed. Proc. 43:1984;276-284.
40. Litchfield J., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.